Conexeu Sciences (CNXU) has drawn fresh attention after launching a preclinical development program for its 3D printed B.R.E.A.S.T. bioregenerative breast matrix at the Wake Forest Institute for Regenerative Medicine.

The recent preclinical program launch and the stock’s addition to the Nasdaq Composite Index have coincided with a 1 day share price return of 20.43% to US$14.12. However, the year to date share price return of 8.03% and a 7 day share price return that declined 1.94% suggest momentum is still forming rather than firmly established.

If this kind of early stage biotech story interests you, it may be worth widening the search to other potential growth ideas using our screener of 40 healthcare AI stocks

With no revenue yet and a market cap of about US$296.3m, Conexeu is being valued purely on its collagen scaffold platform and preclinical pipeline. This raises a key question: is this an early entry point, or is the stock already pricing in future growth?

Preferred Price to Book Multiple of 52.3x: Is It Justified?

Right now, Conexeu is trading on a P/B ratio of 52.3x, compared with 2.6x for the broader US biotech industry and 8.2x for closer peers, even though the company has no revenue and reported a loss of $5.35m.

The P/B ratio compares the stock price to the accounting value of net assets on the balance sheet. A higher multiple usually reflects strong expectations for future earnings power or valuable intangible assets that are not yet visible in current financials.

For an early stage biotech with a collagen scaffold platform still at the preclinical stage, such a large premium suggests the market is placing substantial value on the technology, potential indications and regulatory milestones that may lie ahead, rather than on current financial metrics.

Compared with both the industry average and its peer group, Conexeu’s 52.3x P/B multiple is very high. Investors are paying a much larger price for each dollar of book value than is typical across US biotechs or similar companies.

Result: Price to book ratio of 52.3x (OVERVALUED)

However, such a high P/B on a preclinical, zero revenue business leaves little margin for setbacks if regulatory timelines slip or early data underwhelms.

Next Steps

If this all sounds upbeat or overly cautious, it is worth checking the numbers yourself and deciding how comfortable you are with the early stage risk profile. To see what stands out most, take a closer look at the 2 important warning signs.

Looking for more investment ideas?

If Conexeu has caught your eye, do not stop there. Spread your research across different themes so you are not relying on a single early stage story.

• Target resilient potential by scanning 62 resilient stocks with low risk scores that may help steady your portfolio when sentiment cools.
• Hunt for potential bargains by reviewing 47 high quality undervalued stocks that combine quality fundamentals with pricing that appears undemanding.
• Spot early opportunities by searching a screener containing 22 high quality undiscovered gems before they attract broader attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.